![Christopher Bowden](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Christopher Bowden
Director/Board Member at
BICARA THERAPEUTICS INC.
Net worth: - $ as of 2026-07-30
Profile
Christopher J.
Bowden is Director at Cedilla Therapeutics, Inc. since 2021 and Independent Director at Bicara Therapeutics, Inc. since 2024.
Former roles include Executive Director-Europe, Middle East & Africa at Bristol Myers Squibb Co. from 2003 to 2006; Independent Director at Alaunos Therapeutics, Inc. from 2019 to 2023; Independent Director at Viridian Therapeutics, Inc. from 2017 to 2020; VP-Product Development Oncology at Genentech, Inc. from 2006 to 2014; Chief Medical Officer at Agios Pharmaceuticals, Inc. from 2014 to 2021; Member of Roche Group from 2006 to 2014; and Chief Medical Officer at Remix Therapeutics, Inc. from 2023 to 2025.
Education includes undergraduate studies at Lake Forest College and a doctorate from Drexel University College of Medicine conferred in 1988.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-06-08 | 0 ( -.--% ) | - $ | 2026-07-30 |
Christopher Bowden active positions
| Companies | Position | Start |
|---|---|---|
| BICARA THERAPEUTICS INC. | Director/Board Member | 2024-07-31 |
Cedilla Therapeutics, Inc.
 Cedilla Therapeutics, Inc. BiotechnologyHealth Technology Engages in discovering and exploiting unique insights into protein stability | Director/Board Member | 2021-04-20 |
Former positions of Christopher Bowden
| Companies | Position | End |
|---|---|---|
Remix Therapeutics, Inc.
 Remix Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company develops molecule therapies to modulate RNA processing and address the underlying drivers of diseases | Chief Tech/Sci/R&D Officer | 2025-12-30 |
| ALAUNOS THERAPEUTICS, INC. | Director/Board Member | 2023-03-29 |
| AGIOS PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2021-08-31 |
| VIRIDIAN THERAPEUTICS, INC. | Director/Board Member | 2020-09-30 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Corporate Officer/Principal | 2014-04-30 |
Training of Christopher Bowden
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
87
1st degree connections
11
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 11 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Agios Pharmaceuticals, Inc.
 Agios Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops therapeutics | Health Technology |
Roche Group
 Roche Group Real Estate DevelopmentFinance Manages real estate properties | Finance |
Lake Forest College
 Lake Forest College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Alaunos Therapeutics, Inc.
 Alaunos Therapeutics, Inc. BiotechnologyHealth Technology Develops a portfolio of immuno-oncology therapies | Health Technology |
Drexel University College of Medicine
 Drexel University College of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Viridian Therapeutics, Inc.
 Viridian Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops and manufactures monoclonal antibody products | Health Technology |
Cedilla Therapeutics, Inc.
Cedilla Therapeutics, Inc. BiotechnologyHealth Technology Engages in discovering and exploiting unique insights into protein stability | Health Technology |
Bicara Therapeutics, Inc.
 Bicara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops and sells therapeutics for tumors | Health Technology |
Remix Therapeutics, Inc.
Remix Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company develops molecule therapies to modulate RNA processing and address the underlying drivers of diseases | Health Technology |
- Stock Market
- Insiders
- Christopher Bowden
